IL249578D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
IL249578D0
IL249578D0 IL249578A IL24957816A IL249578D0 IL 249578 D0 IL249578 D0 IL 249578D0 IL 249578 A IL249578 A IL 249578A IL 24957816 A IL24957816 A IL 24957816A IL 249578 D0 IL249578 D0 IL 249578D0
Authority
IL
Israel
Prior art keywords
organic compounds
compounds
organic
Prior art date
Application number
IL249578A
Other languages
Hebrew (he)
Other versions
IL249578A (en
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US32704910P priority Critical
Priority to US36760910P priority
Priority to PCT/US2011/000719 priority patent/WO2011133224A1/en
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IL249578D0 publication Critical patent/IL249578D0/en
Publication of IL249578A publication Critical patent/IL249578A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
IL249578A 2010-04-22 2016-12-15 Substituted heterocycle fused gamma carbolines IL249578A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US32704910P true 2010-04-22 2010-04-22
US36760910P true 2010-07-26 2010-07-26
PCT/US2011/000719 WO2011133224A1 (en) 2010-04-22 2011-04-22 Organic compounds

Publications (2)

Publication Number Publication Date
IL249578D0 true IL249578D0 (en) 2017-02-28
IL249578A IL249578A (en) 2017-12-31

Family

ID=44834444

Family Applications (2)

Application Number Title Priority Date Filing Date
IL222571A IL222571A (en) 2010-04-22 2012-10-21 Substituted heterocycle fused gamma carbolines
IL249578A IL249578A (en) 2010-04-22 2016-12-15 Substituted heterocycle fused gamma carbolines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL222571A IL222571A (en) 2010-04-22 2012-10-21 Substituted heterocycle fused gamma carbolines

Country Status (12)

Country Link
US (2) US8993572B2 (en)
EP (1) EP2560676B8 (en)
JP (1) JP5894574B2 (en)
KR (1) KR101868165B1 (en)
CN (1) CN103209704B (en)
BR (1) BR112012026881A2 (en)
CA (1) CA2796756A1 (en)
ES (1) ES2602503T3 (en)
IL (2) IL222571A (en)
MX (1) MX339805B (en)
RU (1) RU2591194C2 (en)
WO (1) WO2011133224A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102065319B1 (en) * 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Substituted heterocycle fused gamma-carbolines synthesis
US8648077B2 (en) 2008-03-12 2014-02-11 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
KR102133073B1 (en) 2008-05-27 2020-07-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Methods and compositions for sleep disorders and other disorders
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
RU2014145682A (en) 2012-04-14 2016-06-10 Интра-Селлулар Терапиз, Инк ORGANIC COMPOUNDS
JP6549040B2 (en) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New use
WO2014145617A2 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Novel uses
HUE053159T2 (en) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Organic compounds
JP6475727B2 (en) * 2013-12-03 2019-02-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New method
JP2017509686A (en) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
CN106456638A (en) * 2014-04-04 2017-02-22 细胞内治疗公司 Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
DK3177627T3 (en) 2014-08-07 2019-10-21 Intra Cellular Therapies Inc IMIDAZO [1,2-A] -PYRAZOLO [4,3-E] -PYRIMIDIN-4-ON DERIVATIVES WITH PDE1 INHIBITIVE ACTIVITY
AU2015317527B2 (en) 2014-09-17 2020-08-20 Intra-Cellular Therapies, Inc. Compounds and methods
CN104327066B (en) * 2014-09-30 2017-05-24 华东理工大学 Method for rapidly and efficiently extracting carboline alkaloids
KR101613245B1 (en) 2015-04-27 2016-04-18 주식회사 대웅제약 Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
WO2017132408A1 (en) * 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Organic compounds
RU2733975C2 (en) * 2016-03-25 2020-10-08 Интра-Селлулар Терапиз, Инк. Organic compounds
US10654854B2 (en) 2016-03-28 2020-05-19 Intra-Cellular Therapies, Inc. Salts and crystals of ITI-007
JP2019513140A (en) * 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New co-crystal
EP3436083A4 (en) * 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2018106916A1 (en) * 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
EP3562484A4 (en) 2016-12-29 2020-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
RU2019133676A (en) 2017-03-24 2021-04-26 Интра-Селлулар Терапиз, Инк. NEW COMPOSITIONS AND METHODS
US20200247805A1 (en) * 2017-09-26 2020-08-06 Intra-Cellular Therapies, Inc. Novel salts and crystals
CA3102948A1 (en) * 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
US20190388302A1 (en) 2018-06-21 2019-12-26 Aquestive Therapeutics, Inc. System and method for making personalized indvidual unit doses containing pharmaceutical actives
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
US20200101009A1 (en) 2018-09-07 2020-04-02 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
WO2021087359A1 (en) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4001263A (en) * 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
AR206812A1 (en) * 1974-04-01 1976-08-23 Pfizer Azacyclo (3,4-a) indoles 4- and 5-substituted phenyl intermediates devoid of therapeutic activity
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH656884A5 (en) 1983-08-26 1986-07-31 Sandoz Ag Polyolesters, their production and use.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (en) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
SG47445A1 (en) 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
RU2167877C2 (en) * 1995-05-31 2001-05-27 Эйсай Ко., Лтд. Derivatives of condensed polycyclic heterocyclic compounds and method of their synthesis
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
DK1140012T3 (en) * 1998-12-17 2004-07-12 Alza Corp Conversion of liquid filled gelatin capsules to controlled release systems by multiple coatings
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
CA2373920A1 (en) 1999-06-15 2000-12-21 Wei Deng Substituted heterocycle fused gamma-carbolines
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2494234C (en) 2002-07-29 2009-10-27 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
US20040142970A1 (en) 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
AT509929T (en) * 2002-12-19 2011-06-15 Squibb Bristol Myers Co Substituted tricyclic gamma carbolineals serotonin receptor agonists and antagonists
RU2258605C2 (en) * 2004-02-17 2005-08-20 Общество с ограниченной ответственностью "Новые Строительные Технологии" Building mortar preparation and pouring device
EP1756102A1 (en) * 2004-03-05 2007-02-28 Pharma C S.A. 8-PHENOXY-GammaCARBOLINE DERIVATIVES
CA2581023A1 (en) 2004-09-21 2006-03-30 Pfizer Products Inc. N-methyl hydroxyethylamine useful in treating cns conditions
US20080028094A1 (en) * 2006-07-31 2008-01-31 Widerthan Co., Ltd. Method and system for servicing bgm request and for providing sound source information
KR102065319B1 (en) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Substituted heterocycle fused gamma-carbolines synthesis
AU2009212065B2 (en) 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition
US8648077B2 (en) 2008-03-12 2014-02-11 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
KR102133073B1 (en) 2008-05-27 2020-07-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Methods and compositions for sleep disorders and other disorders
EP2560676B8 (en) * 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
RU2014145682A (en) 2012-04-14 2016-06-10 Интра-Селлулар Терапиз, Инк ORGANIC COMPOUNDS
HUE053159T2 (en) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Organic compounds
JP6475727B2 (en) 2013-12-03 2019-02-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New method

Also Published As

Publication number Publication date
KR20130055610A (en) 2013-05-28
KR101868165B1 (en) 2018-07-19
RU2591194C2 (en) 2016-07-10
US9371324B2 (en) 2016-06-21
US20150166540A1 (en) 2015-06-18
ES2602503T3 (en) 2017-02-21
MX339805B (en) 2016-06-10
EP2560676A4 (en) 2013-10-16
IL249578A (en) 2017-12-31
EP2560676B1 (en) 2016-08-10
EP2560676B8 (en) 2016-10-12
MX2012012277A (en) 2013-04-03
IL222571D0 (en) 2012-12-31
IL222571A (en) 2017-12-31
RU2012149633A (en) 2014-05-27
JP5894574B2 (en) 2016-03-30
CN103209704A (en) 2013-07-17
BR112012026881A2 (en) 2017-10-10
WO2011133224A1 (en) 2011-10-27
EP2560676A1 (en) 2013-02-27
US20130202692A1 (en) 2013-08-08
CN103209704B (en) 2017-10-27
JP2013525352A (en) 2013-06-20
CA2796756A1 (en) 2011-10-27
US8993572B2 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
IL249578D0 (en) Organic compounds
EP2575817A4 (en) Organic compounds
EP2576550A4 (en) Organic compounds
EP2576551A4 (en) Organic compounds
EP2590657A4 (en) Organic compounds
IL223783D0 (en) Pro-neurogenic compounds
EP2717877A4 (en) Organic compounds
ZA201306056B (en) Organic compounds
GB201007347D0 (en) Compounds
EP2605658A4 (en) Spiroxazolidinone compounds
EP2649050A4 (en) Compounds
IL222313D0 (en) Combination of organic compounds
GB201001688D0 (en) Compounds
GB201008209D0 (en) Compounds
EP2788385A4 (en) Organic compounds
EP2723173A4 (en) Organic compounds
GB201021584D0 (en) Organic compounds
EP2593106A4 (en) Organic compounds
GB201015537D0 (en) Compounds
GB201002216D0 (en) Compounds
GB201020070D0 (en) Organic compounds
GB201018171D0 (en) Organic compounds
GB201118481D0 (en) Organic compounds
GB201021087D0 (en) Organic compounds
GB201006639D0 (en) Organic compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed